<DOC>
	<DOCNO>NCT01897896</DOCNO>
	<brief_summary>The purpose study evaluate safety , tolerability pharmacokinetics SD-809 ER subject switch tetrabenazine SD-809 ER . In addition , safety tolerability long term treatment SD-809 ER assess `` Switch '' subject well `` Rollover '' subject complete randomize , double blind , placebo control study SD-809 ER ,</brief_summary>
	<brief_title>Alternatives Reducing Chorea HD</brief_title>
	<detailed_description />
	<mesh_term>Huntington Disease</mesh_term>
	<mesh_term>Chorea</mesh_term>
	<criteria>1 . Subject least 18 year age age majority ( whichever old ) Screening . 2 . Subject diagnosed manifest HD , indicate characteristic motor exam feature , document expand CAG repeat ( ≥ 37 ) Screening . 3 . Subject meet either follow : Has successfully complete participation FirstHD Study ( SD809C15 ) OR Has receive FDAapproved dose tetrabenazine stable ≥ 8 week Screening provide therapeutic benefit control chorea . 4 . Subject Total Functional Capacity ( TFC ) score ≥ 5 Screening . 5 . Subject able swallow study medication whole . 6 . Subject provide write , informed consent , legally authorize representative ( LAR ) provide write informed consent subject provide assent . 7 . Subject provide Research Advance Directive . 8 . Female subject childbearing potential agree use acceptable method contraception screen study completion . 9 . The subject reliable caregiver interacts patient daily basis , oversee study drug administration , assure attendance study visit participates evaluation , require . 10 . Subject able ambulate without assistance least 20 yard ( Note : The use assistive device ( i.e. , walker , cane ) permit ambulation ) . 11 . Has sufficient reading skill comprehend subject complete rating scale . 1 . Subject serious untreated undertreated psychiatric illness , depression , Screening Baseline . 2 . Subject active suicidal ideation Screening Baseline . 3 . Subject history suicidal behavior Screening Baseline . 4 . Subject evidence depression Baseline . 5 . Subject unstable serious medical illness Screening Baseline . 6 . Subject receive tetrabenazine within 7 day Baseline ( Rollover subject ) . 7 . Subject receive follow concomitant medication within 30 day Screening Baseline : Antipsychotics Metoclopramide Monoamine oxidase inhibitor ( MAOI ) Levodopa dopamine agonist Reserpine Amantadine Memantine ( Rollover subject ) Switch subject may receive Memantine stable , approve dose least 30 day 8 . Subject significantly impaired swallow function Screening Baseline . 9 . Subject significantly impaired speak Screening Baseline . 10 . Subject require treatment drug know prolong QT interval . 11 . Subject prolonged QT interval 12lead ECG Screening . 12 . Subject evidence hepatic impairment Screening . 13 . Subject evidence significant renal impairment Screening . 14 . Subject know allergy component study medication . 15 . Subject participate investigational drug device trial SD809C15 within 30 day ( 5 drug halflives ) Screening , whichever longer . 16 . Subject pregnant breastfeeding Screening Baseline . 17 . Subject acknowledges present use illicit drug Screening Baseline . 18 . Subject history alcohol substance abuse previous 12 month .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>December 2016</verification_date>
	<keyword>Chorea</keyword>
	<keyword>Huntington Disease</keyword>
</DOC>